PCV Chemotherapy for Oligodendroglioma: Response Analyzed on T2 Weighted-MRI

Overview

Journal J Neurooncol

Publisher Springer

Date 2002 Jan 24

PMID 11804282

Citations 3

Authors

S Diabira

M C Rousselet

E Gamelin

P Soulier

E Jadaud

P Menei

Affiliations

Soon will be listed here.

Abstract

Objective: Because oligodendroglioma are infiltrative tumors, the Mac Donald's response criteria, usually used for solid and contrast-enhanced tumors, seem not to be adapted. To precise more relevant radiological criteria, the radiological response of oligodendroglioma to PCV chemotherapy was evaluated on T2 weighted-MRI sequences only.

Methods: 25 patients with oligodendroglioma grade A or B were retrospectively analyzed. They were treated with up to six cycles of PCV standard regimen. Tumor size was calculated before and at the end of the treatment, on T2 weighted-MRI, by two methods: volumetric reconstruction (method 1) and maximal cross-sectional area (method 2). Responses were defined according to new criteria on T2 weighted-MRI.

Results: According to these criteria and with the method 1, 7 of 25 patients (28%) had a partial response to the PCV, 14 patients (56%) had stabilized disease, and 4 patients (16%) had progressive disease. With the method 2, 6 had partial response (24%), 18 had stabilized disease (72%) and 1 had progressive disease.

Conclusion: Response rate to PCV chemotherapy in this study was lower than response observed in the literature. Because of the infiltrative feature of oligodendroglioma, we think that the radiological response of these tumors should be evaluated on T2 weighted-MRI. The two methods of tumor size estimation used in this study were almost equivalent. Then, the maximal cross-sectional area measurement, more practical, could be retained.

Citing Articles

Clinical and radiological features of pediatric cerebellar anaplastic oligodendrogliomas.

Furtado S, Venkatesh P, Ghosal N, Murthy G, Hegde A Indian J Pediatr. 2011; 78(7):880-3.

PMID: 21243536 DOI: 10.1007/s12098-010-0318-4.

Proposal of a scoring scale as a survival predictor in intracranial oligodendrogliomas.

Hamlat A, Saikali S, Chaperon J, Carsin-Nicol B, Le Calve M, Lesimple T J Neurooncol. 2006; 79(2):159-68.

PMID: 16821091 DOI: 10.1007/s11060-005-9026-8.

Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma.

Tang B, Sadeghi N, Branle F, De Witte O, Wikler D, Goldman S J Neurooncol. 2005; 71(2):161-8.

PMID: 15690133 DOI: 10.1007/s11060-004-9654-4.

References

Mason W, Krol G, DeAngelis L . Low-grade oligodendroglioma responds to chemotherapy. Neurology. 1996; 46(1):203-7. DOI: 10.1212/wnl.46.1.203. View

Daumas-Duport C, Tucker M, Kolles H, Cervera P, Beuvon F, Varlet P . Oligodendrogliomas. Part II: A new grading system based on morphological and imaging criteria. J Neurooncol. 1997; 34(1):61-78. DOI: 10.1023/a:1005759220434. View

Daumas-Duport C, Varlet P, Tucker M, Beuvon F, Cervera P, Chodkiewicz J . Oligodendrogliomas. Part I: Patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases. J Neurooncol. 1997; 34(1):37-59. DOI: 10.1023/a:1005707203596. View

Kyritsis A, Yung W, BRUNER J, Gleason M, Levin V . The treatment of anaplastic oligodendrogliomas and mixed gliomas. Neurosurgery. 1993; 32(3):365-70; discussion 371. DOI: 10.1227/00006123-199303000-00005. View

Peterson K, Paleologos N, Forsyth P, Macdonald D, Cairncross J . Salvage chemotherapy for oligodendroglioma. J Neurosurg. 1996; 85(4):597-601. DOI: 10.3171/jns.1996.85.4.0597. View

Macdonald D, Cascino T, Schold Jr S, Cairncross J . Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990; 8(7):1277-80. DOI: 10.1200/JCO.1990.8.7.1277. View

Bruner J . Neuropathology of malignant gliomas. Semin Oncol. 1994; 21(2):126-38. View

Daumas-Duport C . Histoprognosis of gliomas. Adv Tech Stand Neurosurg. 1994; 21:43-76. DOI: 10.1007/978-3-7091-6648-2_2. View

Daumas-Duport C, Monsaigneon V, Blond S, Munari C, Musolino A, Chodkiewicz J . Serial stereotactic biopsies and CT scan in gliomas: correlative study in 100 astrocytomas, oligo-astrocytomas and oligodendrocytomas. J Neurooncol. 1987; 4(4):317-28. DOI: 10.1007/BF00195602. View

10.

Bouffet E, Mornex F, Jouvet A, Thiesse P, Mertens P, Helfre S . [Assessment of procarbazine, vincristine and lomustine association (PCV protocol) in oligodendroglioma and mixed glioma]. Bull Cancer. 1998; 84(10):951-6. View

11.

van den Bent M, Kros J, Heimans J, Pronk L, Van Groeningen C, Krouwer H . Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology. 1998; 51(4):1140-5. DOI: 10.1212/wnl.51.4.1140. View

12.

Cairncross J, Macdonald D . Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol. 1988; 23(4):360-4. DOI: 10.1002/ana.410230408. View

13.

Daumas-Duport C, Monsaingeon V, SZENTHE L, SZIKLA G . Serial stereotactic biopsies: a double histological code of gliomas according to malignancy and 3-D configuration, as an aid to therapeutic decision and assessment of results. Appl Neurophysiol. 1982; 45(4-5):431-7. DOI: 10.1159/000101638. View

14.

Glass J, Hochberg F, Gruber M, Louis D, Smith D, Rattner B . The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. J Neurosurg. 1992; 76(5):741-5. DOI: 10.3171/jns.1992.76.5.0741. View

15.

Coons S, Johnson P, Scheithauer B, Yates A, Pearl D . Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer. 1997; 79(7):1381-93. DOI: 10.1002/(sici)1097-0142(19970401)79:7<1381::aid-cncr16>3.0.co;2-w. View

16.

Levin V, Edwards M, Wright D, Seager M, Schimberg T, Townsend J . Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat Rep. 1980; 64(2-3):237-44. View

17.

Kelly P, Daumas-Duport C, Scheithauer B, Kall B, Kispert D . Stereotactic histologic correlations of computed tomography- and magnetic resonance imaging-defined abnormalities in patients with glial neoplasms. Mayo Clin Proc. 1987; 62(6):450-9. DOI: 10.1016/s0025-6196(12)65470-6. View

18.

Soffietti R, Ruda R, Bradac G, Schiffer D . PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery. 1998; 43(5):1066-73. DOI: 10.1097/00006123-199811000-00035. View

19.

Macdonald D, Gaspar L, Cairncross J . Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann Neurol. 1990; 27(5):573-4. DOI: 10.1002/ana.410270519. View

20.

Cairncross J, Macdonald D, Ramsay D . Aggressive oligodendroglioma: a chemosensitive tumor. Neurosurgery. 1992; 31(1):78-82. DOI: 10.1227/00006123-199207000-00011. View